One year post-procedure outcomes
| ATLAS subjects who met comparator trial inclusion/exclusion criteria | Comparator trial | P value | |||
| Crude | MAIC weighted | ||||
| Comparator trial | Outcome | ||||
| LVIS | Primary safety | 11/241 (4.6) | 7/184 (3.6) | 8/153 (5.2) | 0.43 |
| Primary effectiveness | 166/207 (80.2) | 132/157 (84.2) | 108/139 (77.7) | 0.12 | |
| Complete occlusion | 172/201 (85.6) | 136/154 (88.2) | 110/139 (79.1) | 0.02 | |
| Retreatment | 10/241 (4.2) | 4/184 (2.4) | 2/153 (1.3) | 0.44 | |
| WEB-IT | Primary safety | 5/141 (3.6) | 4/109 (3.7) | 1/148 (0.7) | 0.06 |
| Primary effectiveness | 107/124 (86.3) | 79/91 (86.6) | 77/143 (53.9) | <0.0001 | |
| Complete occlusion | 111/122 (91.0) | 81/90 (90.3) | 77/143 (53.9) | <0.0001 | |
| Retreatment | 5/141 (3.6) | 3/109 (2.4) | 14/143 (9.8) | 0.01 | |
ATLAS, Safety and Effectiveness of the Treatment of Wide Neck, Saccular Intracranial Aneurysms With the Neuroform Atlas Stent System; LVIS, Pivotal Study of the Low Profile Visualized Intraluminal Support; MAIC, matching adjusted indirect comparison method; WEB-IT, Woven EndoBridge Intrasaccular Therapy Study.